Description
I was invited to this meeting to present our research data pertaining to the risks associated with prenatal exposure to valproate. This was part of a series of meetings for the Article 31 Referral regarding valproate use in pregnancy. Following the completion of this review the European Medicines Agency announced measures to restrict the prescribing of valproate in women and girls of childbearing age.| Period | 26 Feb 2014 |
|---|
Keywords
- Teratology
- Regulators
- Epilepsy
- Pregnancy
- pharmacovigilance
- Neuropsychology
- Neurodevelopment
Documents & Links
Related content
-
Research output
-
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Research output: Contribution to journal › Article › peer-review
-
Breastfeeding in children of women taking antiepileptic drugs: Cognitive outcomes at age 6 years
Research output: Contribution to journal › Article › peer-review
-
Child development following in utero exposure: levetiracetam vs sodium valproate.
Research output: Contribution to journal › Article › peer-review
-
In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.
Research output: Contribution to journal › Article › peer-review
-
The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs
Research output: Contribution to journal › Article › peer-review
-
Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study
Research output: Contribution to journal › Article › peer-review
-
Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Research output: Contribution to journal › Article › peer-review
-
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate
Research output: Contribution to journal › Article › peer-review